The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
4
Covance
Dallas, Texas, United States
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
Time frame: Baseline through study completion (up to 109 days)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3478006
Cmax of LY3478006 was evaluated.
Time frame: Predose; Day 1 with end of infusion, 3, 6, 12 hours
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC0-∞) of LY3478006
AUC0-∞ of LY3478006 was evaluated. The unit of measure is hour\*microgram per milliliter (hr\*mcg/mL).
Time frame: Predose; Day 1 with end of infusion, 3, 6, 12 hours; Day 2; Day 3; Day 5; Day 8; Day 10; Day 15; Day 22; Day 29; Day 43; Day 57; Day 71 and Day 85
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered SC